



These changes and additions apply to Exchange formularies and are effective 12/15/23.

Additions

- **Abrysvo (respiratory syncytial virus vaccine)** – Medical/Pharmacy benefit, Non-Preferred brand, No PA for 60+ age, no copay. Medical – no PA.
- **Arexvy (respiratory syncytial virus vaccine recombinant, adjuvanted)** – Medical/Pharmacy benefit, Non-preferred brand, No PA for 60+ age, no copay. Medical – no PA.
- **Beyfortus (nirsevimab-alip)** – Medical benefit, no PA, no copay
- **Inpefa (sotagliflozin)** – Pharmacy benefit, Non-Preferred brand, PA
- **Izervay (avacincaptad pegol)** – Medical benefit, PA
- **Zavzpret (zavegepant)** – Pharmacy benefit, Non-Preferred brand, PA and QL of 12 per 30 days
- **Veozah (fezolinetant)** – Pharmacy benefit, Non-Preferred brand, PA and QL of 1 per day
- **Rystiggo (rozanolixizumab-noli)** – Medical benefit, PA
- **Vyvgart Hytrulo (efgartigimod alfa/ hyaluronidase-qvfc)** – Medical benefit, PA
- **Elrexio (elranatamab-bcmm)** – Medical benefit, PA
- **Talvey (talquetamab-tgvs)** – Medical benefit, PA
- **Vanflyta (quizartinib)** – Pharmacy benefit, Non-Preferred brand, SCC PA and QL of 1 per day for 17.7mg and 2 per day for 26.5mg
- **Veopoz (pozelimab-bbfg)** – Medical benefit, PA
- **Narcan 4mg or naloxone 4mg OTC** – Pharmacy benefit, Non-Preferred brand/generic, no PA or copay
- **Brixadi (buprenorphine)** – Medical benefit, no PA
- **Eylea HD (aflibercept)** – Medical benefit, PA
- **Step Therapy Exception Policy** – Pharmacy/Medical benefit, policy created
- **Brenzavvy (bexagliflozin)** – Pharmacy benefit, Non-Formulary

Changes

- **Rinvoq (upadacitinib)** – Pharmacy benefit, update to PA criteria, add AS and nr-AxSpA indications
- **Dupixent (dupilumab)** – Pharmacy benefit, update to PA criteria, add EoE and prurigo nodularis indications. Age update to AD
- **Opzelura (ruxolitinib)** – Pharmacy benefit, update to PA criteria, add nonsegmental vitiligo indication
- **Wakix (pitolisant)** – Pharmacy benefit, update to PA criteria, add Narcolepsy with Cataplexy indication
- **Livmarli (maralixibat)** – Pharmacy benefit, update to PA criteria, remove age
- **Takhzyro (lanadelumab-flyo)** – Pharmacy benefit, update to PA criteria, remove age
- **Odactra House Dust Mite** – Pharmacy benefit, update to PA criteria, age update